Clinical Consultations™: Perspectives on Managing Retinal Diseases – Streamlining the Pathway from Diagnosis to Treatment

Release Date: December 23, 2020
Expiration Date: December 23, 2021

Activity Overview

Diabetic eye diseases and age-related macular degeneration (AMD) are the most common retinal diseases. Diabetic retinopathy (DR) is the leading cause of blindness in the United States for adults ages 20 to 74; worldwide, 34.6% of individuals with diabetes have DR, 10.2% have vision-threatening DR, and 6.8% have diabetic macular edema (DME). AMD affects approximately 11 million Americans, with the prevalence expected to double by 2050, given an aging population.

In this program, expert faculty will provide insights into the diagnosis and management of DR, DME, and AMD. They will outline patient evaluations, retinal imaging, and therapeutic choices. They will also review the role of the multidisciplinary team in the overall management of these eye diseases.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Regeneron Pharmaceuticals Inc.

Target Audience

This activity is intended for ophthalmologists, optometrists, retinal specialists, diabetologists, primary care physicians, and other health care professionals who may encounter patients with retinal diseases in clinical practice.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Review risk factors for DR, DME, and neovascular AMD, as well as their etiology and typical progression
• Describe the guideline-recommended screening strategies for DR, DME, and neovascular AMD, and the optimal use of imaging technologies in screening and diagnosis
• Evaluate the appropriate patients, risks, benefits, and guideline recommendations for DR, DME, and neovascular AMD therapies
• Identify opportunities for eyecare providers to provide team-based care for DR, DME, and neovascular AMD alongside primary care providers and other specialists

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Quan Dong Nguyen, MD, MSc, FAAO, FARVO
Professor of Ophthalmology
Uveitis and Ocular Inflammatory Diseases
Medical and Surgical Diseases of the Retina and Vitreous
Director of Uveitis and Ocular Inflammation Service
Byers Eye Institute
Stanford University School of Medicine
Palo Alto, CA

Disclosures: Grant/Research Support: Genentech, Gilead, Novartis, Regeneron, Santen. Consultant: Adverum, Bayer, Regeneron, Santen

A. Paul Chous, MA, OD, FAAO
Medical Director, Chous Eye Care Associates,
Tacoma,WA
Adjunct Professor, Western University of Health Sciences
Pomona, CA

Disclosures: Grant/Research Support: ZeaVision, LLC ; Consultant: ZeaVision, LLC, Regeneron, Genentech, Zeiss, VSP; Speaker's Bureau: ZeaVision, Regeneron, Genentech, Zeiss, VSP.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.